Edesa Biotech is trading 7.06% up in pre-market at $5.61 after positive immunology-sector sentiment linked to argenx’s approximately $2.2 billion acquisition of Forte Biosciences.
- The transaction includes a $77-per-share cash tender offer and expands argenx’s autoimmune and vitiligo pipeline.
- Argenx announced the tender offer on August 6, 2026; no new Edesa-specific announcement was identified for August 11.
- The move follows Edesa’s August 10 close of $5.24, while broader U.S. index futures were modestly higher.